With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: It has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, while the trial group with Merck’s drug had only 7% hospitalized and zero deaths.

This appears to be just the tip of the iceberg; Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Latest

Simply Shipped: How Technology Accelerates Logistics Engines
September 30, 2022
 Since the COVID-19 pandemic erupted, we have constantly been hearing about supply chain shortages and backups causing delays in product deliveries in multiple sectors. Sanil Mahajan, Global Head – Read more
Beyond the Concept: Managing the Risk of Using Out-of-Date Parts and Products in a Facility
September 30, 2022
 Facilities can ill afford to have equipment go down with today’s supply chain challenges. Lost hours could quickly become lost days if a replacement is unavailable. Sam Cafferata, Principal Engineer Read more
Highlights of the 2022 Battery Show
The Most POWERFUL Conference of the Year, The Battery Show 2022
September 30, 2022
Grant Harrell, host of Are We There Yet? had the pleasure of attending Informa Markets’ The Battery Show in Novi, Michigan from September 13-15, 2022. The show featured the latest trends and topics Read more